-
公开(公告)号：US08426376B2
公开(公告)日：2013-04-23
申请号：US12702272
申请日：2010-02-08
Applicant: Yasufumi Sato , Hikaru Sonoda , Hideki Ohta
Inventor： Yasufumi Sato , Hikaru Sonoda , Hideki Ohta
IPC: A61K31/7088 , C12Q1/68 , A61P9/10
CPC classification number: A61K45/06 , A61K31/7088 , A61K38/00 , C07K14/4703 , C07K16/22 , G01N33/574 , G01N2333/515 , G01N2500/04 , Y10T436/143333 , A61K2300/00
Abstract: Because AK022567 has angiogenesis inhibitory activity, it is useful as an angiogenesis inhibitor. Furthermore, 4 splicing variants obtained from the same gene are also useful as an angiogenesis inhibitor. These 5 polypeptides, polynucleotides encoding the polypeptides and antibodies against the polypeptides are useful for screening of a candidate compound as an angiogenesis inhibitor or promoter. A compound obtained from the screening is useful as a medicine and can be used for a preventive or therapeutic agent for an angiogenesis related disease.
Abstract translation: 由于AK022567具有血管发生抑制活性，因此可用作血管生成抑制剂。 此外，从相同基因获得的4个剪接变体也可用作血管发生抑制剂。 这5种多肽，编码多肽的多核苷酸和针对多肽的抗体可用于筛选作为血管生成抑制剂或启动子的候选化合物。 从筛选获得的化合物可用作药物，并且可用于血管生成相关疾病的预防或治疗剂。
-
公开(公告)号：US07956036B2
公开(公告)日：2011-06-07
申请号：US12027873
申请日：2008-02-07
Applicant: Yasufumi Sato , Hikaru Sonoda , Hideki Ohta
Inventor： Yasufumi Sato , Hikaru Sonoda , Hideki Ohta
IPC: C12N5/00 , A61K38/17 , A61K31/711 , C12Q1/68 , A61P35/00
CPC classification number: C12Q1/6883 , A61K38/00 , C07K14/47 , C12N2799/026 , C12Q2600/158
Abstract: A marker for neovascularization, vascular disease, inflammatory disease, entoptic neovascular disease, reproductive system disease, central nervous system disease and cancer, the method of detection of the marker and a diagnosis kit of the diseases are provided. Additionally, therapeutic agents of the diseases are provided.The expression of KIAA1036 is enhanced in ovarian cancer and large bowel cancer and KIAA1036 expresses in umbilical vein endothelial cell and inhibits DNA synthesis in the cells, cell migrating and lumen formation. Therefore KIAA1036 is useful as a marker for neovascularization, vascular disease, inflammatory disease, entoptic neovascular disease, reproductive system disease, central nervous system disease or cancer. Additionally, KIAA1036 is useful for screening of agonists, antagonists, DNA synthesis inhibitors, cell migrating inhibitors and neovascular inhibitors. The substances obtained by the screening, KIAA1036 and the antibodies are useful as therapeutic agents the above disease.
Abstract translation: 提供新生血管形成，血管疾病，炎性疾病，新生血管新生血管疾病，生殖系统疾病，中枢神经系统疾病和癌症的标志物，检测标志物的方法和疾病的诊断试剂盒。 此外，提供了疾病的治疗剂。 KIAA1036在卵巢癌和大肠癌中的表达增强，KIAA1036在脐静脉内皮细胞中表达，抑制细胞中的DNA合成，细胞迁移和管腔形成。 因此，KIAA1036可用作新生血管形成，血管疾病，炎性疾病，新生血管新生，生殖系统疾病，中枢神经系统疾病或癌症的标志物。 另外，KIAA1036可用于筛选激动剂，拮抗剂，DNA合成抑制剂，细胞迁移抑制剂和新生血管抑制剂。 通过筛选获得的物质，KIAA1036和抗体可用作上述疾病的治疗剂。
-
公开(公告)号：US20110065641A1
公开(公告)日：2011-03-17
申请号：US12950953
申请日：2010-11-19
Applicant: YASUFUMI SATO , HIKARU SONODA , HIDEKI OHTA
Inventor： YASUFUMI SATO , HIKARU SONODA , HIDEKI OHTA
CPC classification number: C12Q1/6883 , A61K38/00 , C07K14/47 , C12N2799/026 , C12Q2600/158
Abstract: A marker for neovascularization, vascular disease, inflammatory disease, entoptic neovascular disease, reproductive system disease, central nervous system disease and cancer, the method of detection of the marker and a diagnosis kit of the diseases are provided. Additionally, therapeutic agents of the diseases are provided.The expression of KIAA1036 is enhanced in ovarian cancer and large bowel cancer and KIAA1036 expresses in umbilical vein endothelial cell and inhibits DNA synthesis in the cells, cell migrating and lumen formation. Therefore KIAA1036 is useful as a marker for neovascularization, vascular disease, inflammatory disease, entoptic neovascular disease, reproductive system disease, central nervous system disease or cancer. Additionally, KIAA1036 is useful for screening of agonists, antagonists, DNA synthesis inhibitors, cell migrating inhibitors and neovascular inhibitors. The substances obtained by the screening, KIAA1036 and the antibodies are useful as therapeutic agents the above disease.
Abstract translation: 提供新生血管形成，血管疾病，炎性疾病，新生血管新生血管疾病，生殖系统疾病，中枢神经系统疾病和癌症的标志物，检测标记物的方法和疾病的诊断试剂盒。 此外，提供了疾病的治疗剂。 KIAA1036在卵巢癌和大肠癌中的表达增强，KIAA1036在脐静脉内皮细胞中表达，抑制细胞中的DNA合成，细胞迁移和管腔形成。 因此，KIAA1036可用作新生血管形成，血管疾病，炎性疾病，新生血管新生，生殖系统疾病，中枢神经系统疾病或癌症的标志物。 另外，KIAA1036可用于筛选激动剂，拮抗剂，DNA合成抑制剂，细胞迁移抑制剂和新生血管抑制剂。 通过筛选获得的物质，KIAA1036和抗体可用作上述疾病的治疗剂。
-
公开(公告)号：US20100256224A1
公开(公告)日：2010-10-07
申请号：US12702272
申请日：2010-02-08
Applicant: YASUFUMI SATO , HIKARU SONODA , HIDEKI OHTA
Inventor： YASUFUMI SATO , HIKARU SONODA , HIDEKI OHTA
IPC: A61K31/7088 , C12Q1/68 , A61P9/10
CPC classification number: A61K45/06 , A61K31/7088 , A61K38/00 , C07K14/4703 , C07K16/22 , G01N33/574 , G01N2333/515 , G01N2500/04 , Y10T436/143333 , A61K2300/00
Abstract: Because AK022567 has angiogenesis inhibitory activity, it is useful as an angiogenesis inhibitor. Furthermore, 4 splicing variants obtained from the same gene are also useful as an angiogenesis inhibitor. These 5 polypeptides, polynucleotides encoding the polypeptides and antibodies against the polypeptides are useful for screening of a candidate compound as an angiogenesis inhibitor or promoter. A compound obtained from the screening is useful as a medicine and can be used for a preventive or therapeutic agent for an angiogenesis related disease.
Abstract translation: 由于AK022567具有血管发生抑制活性，因此可用作血管生成抑制剂。 此外，从相同基因获得的4个剪接变体也可用作血管发生抑制剂。 这5种多肽，编码多肽的多核苷酸和针对多肽的抗体可用于筛选作为血管生成抑制剂或启动子的候选化合物。 从筛选获得的化合物可用作药物，并且可用于血管生成相关疾病的预防或治疗剂。
-
公开(公告)号：US20090270314A1
公开(公告)日：2009-10-29
申请号：US12088234
申请日：2006-09-27
Applicant: Yasufumi Sato , Hikaru Sonoda , Hideki Ohta
Inventor： Yasufumi Sato , Hikaru Sonoda , Hideki Ohta
CPC classification number: C07K14/47 , A61K38/00 , G01N33/5011 , G01N33/57496 , G01N2333/475
Abstract: The present inventors found out four kinds of fragments (42 kD, 36 kD, 32 kD, 27 kD) by forcibly expressing vasohibin in a vascular endothelial cell. The present inventors analyzed those fragments and, as a result, found out low molecular weight vasohibin which has an anti-angiogenic activity. The low molecular weight vasohibin is useful as a therapeutic agent for various diseases such as a vascular disease associated with angiogenesis, an inflammatory disease, an entoptic neovascular disease, a reproductive disease, a central nervous system disease and cancer and the like. In addition, the low molecular weight vasohibin is also useful as a marker for angiogenesis.
Abstract translation: 本发明人通过在血管内皮细胞中强制表达血管舒缓，发现了四种片段（42kD，36kD，32kD，27kD）。 本发明人分析了这些片段，结果发现具有抗血管生成活性的低分子量血管舒缓素。 低分子量血管舒缓剂可用作各种疾病的治疗剂，例如与血管发生，炎性疾病，内在的新血管病，生殖疾病，中枢神经系统疾病和癌症等有关的血管疾病。 此外，低分子量血管舒张也可用作血管生成的标志物。
-
Patent Agency Ranking
公开(公告)号：US20080269129A1
公开(公告)日：2008-10-30
申请号：US12027873
申请日：2008-02-07
Applicant: Yasufumi SATO , Hikaru Sonoda , Hideki Ohta
Inventor： Yasufumi SATO , Hikaru Sonoda , Hideki Ohta
IPC: A61K38/17 , C12N5/00 , A61K31/711 , C12Q1/68 , A61P35/00
CPC classification number: C12Q1/6883 , A61K38/00 , C07K14/47 , C12N2799/026 , C12Q2600/158
Abstract: A marker for neovascularization, vascular disease, inflammatory disease, entoptic neovascular disease, reproductive system disease, central nervous system disease and cancer, the method of detection of the marker and a diagnosis kit of the diseases are provided. Additionally, therapeutic agents of the diseases are provided.The expression of KIAA1036 is enhanced in ovarian cancer and large bowel cancer and KIAA1036 expresses in umbilical vein endothelial cell and inhibits DNA synthesis in the cells, cell migrating and lumen formation. Therefore KIAA1036 is useful as a marker for neovascularization, vascular disease, inflammatory disease, entoptic neovascular disease, reproductive system disease, central nervous system disease or cancer. Additionally, KIAA1036 is useful for screening of agonists, antagonists, DNA synthesis inhibitors, cell migrating inhibitors and neovascular inhibitors. The substances obtained by the screening, KIAA1036 and the antibodies are useful as therapeutic agents the above disease.
Abstract translation: 提供新生血管形成，血管疾病，炎性疾病，新生血管新生血管疾病，生殖系统疾病，中枢神经系统疾病和癌症的标志物，检测标记物的方法和疾病的诊断试剂盒。 此外，提供了疾病的治疗剂。 KIAA1036在卵巢癌和大肠癌中的表达增强，KIAA1036在脐静脉内皮细胞中表达，抑制细胞中的DNA合成，细胞迁移和管腔形成。 因此，KIAA1036可用作新生血管形成，血管疾病，炎性疾病，新生血管新生，生殖系统疾病，中枢神经系统疾病或癌症的标志物。 另外，KIAA1036可用于筛选激动剂，拮抗剂，DNA合成抑制剂，细胞迁移抑制剂和新生血管抑制剂。 通过筛选获得的物质，KIAA1036和抗体可用作上述疾病的治疗剂。
-
公开(公告)号：US08909124B2
公开(公告)日：2014-12-09
申请号：US12910192
申请日：2010-10-22
Applicant: Takashi Kuwata , Kenji Abe , Hideki Ohta , Takamichi Matsuo , Youhei Suzuki , Takuro Mita
Inventor： Takashi Kuwata , Kenji Abe , Hideki Ohta , Takamichi Matsuo , Youhei Suzuki , Takuro Mita
CPC classification number: G03G15/205 , G03G15/2028 , G03G15/234 , G03G15/6579 , G03G2215/0043 , G03G2215/00586 , G03G2215/00599 , G03G2215/00772
Abstract: An image forming apparatus includes a sheet feed unit which feeds a sheet to an image forming unit forming an image on the sheet, a re-transport roller which reverses the sheet with a toner image fixed on the sheet and re-transports the sheet to the image forming unit, and a control unit which controls a sheet feed operation of the sheet feed unit for feeding the sheet. As the temperature of the re-transport roller sensed by the temperature sensing unit is decreased, the control unit retards the timing at which the sheet feed unit starts the sheet feed operation when a duplex image formation in which the image is formed on both sides of the sheet is performed after a one-side image formation is completed.
Abstract translation: 图像形成装置包括将片材供给到在片材上形成图像的图像形成单元的片材进给单元，将固定在片材上的调色剂图像反转片材的再传送辊，并将片材重新输送到片材 图像形成单元，以及控制用于供给片材的供纸单元的片材进给操作的控制单元。 当由温度检测单元检测到的再传送辊的温度降低时，控制单元延迟供纸单元开始进纸操作的定时，当在其中形成图像的双面图像形成时， 在单面图像形成完成之后执行片材。
-
公开(公告)号：US08755734B2
公开(公告)日：2014-06-17
申请号：US12905198
申请日：2010-10-15
Applicant: Kenji Abe , Hideki Ohta , Takashi Kuwata , Youhei Suzuki , Takamichi Matsuo , Toshiaki Sako
Inventor： Kenji Abe , Hideki Ohta , Takashi Kuwata , Youhei Suzuki , Takamichi Matsuo , Toshiaki Sako
IPC: G03G15/00
CPC classification number: G03G15/6579 , G03G15/234 , G03G15/6508 , G03G15/6529 , G03G2215/0043 , G03G2215/00586
Abstract: An image forming apparatus includes: a sheet feed unit that feeds a sheet to an image forming unit forming a toner image on the sheet; a fixing unit that fixes the toner image formed in the image forming unit to the sheet; and a control unit that controls the sheet feed unit, when starting duplex image formation for forming both sides of the sheet after an one-side image formation, the control unit retards a timing to cause the sheet feed unit to start the sheet feed operation as the number of sheet with an image formed on one side thereof in the one-side image formation is greater.
Abstract translation: 图像形成装置包括：片材馈送单元，其将片材馈送到在片材上形成调色剂图像的图像形成单元; 固定单元，其将形成在图像形成单元中的调色剂图像定影到片材; 以及控制单元，其控制所述供纸单元，当在单面图像形成之后开始用于形成纸张的两面的双面图像形成时，所述控制单元延迟所述供纸单元开始所述供纸操作的定时，作为 在单面图像形成中在其一侧形成的图像的数量更多。
-
公开(公告)号：US20090203039A1
公开(公告)日：2009-08-13
申请号：US12375210
申请日：2007-07-27
Applicant: Goro Kominami , Masahiro Nakamura , Noriaki Kume , Hideki Ohta
Inventor： Goro Kominami , Masahiro Nakamura , Noriaki Kume , Hideki Ohta
CPC classification number: C07K16/28 , C07K2317/92
Abstract: It is intended to provide a monoclonal antibody that specifically recognizes human soluble LOX-1, particularly a monoclonal antibody with a dissociation constant (Kd) for human soluble LOX-1 of 1×10−9 (M) or less. The antibody can be produced from a hybridoma prepared by a method including the following steps of: (1) immunizing a non-human animal with a prokaryotic cell-derived human LOX-1 extracellular domain; (2) collecting antibody-producing cells from the animal; (3) fusing the antibody-producing cells with myeloma cells; (4) selecting hybridomas that produce a monoclonal antibody reacting with the human LOX-1 extracellular domain from the fused cells obtained in the above step; and (5) selecting a hybridoma that produces a monoclonal antibody reacting with a eukaryotic cell-derived human LOX-1 extracellular domain from the selected hybridomas.
Abstract translation: 旨在提供特异性识别人可溶性LOX-1的单克隆抗体，特别是具有1x10-9（M）以下的人可溶性LOX-1的解离常数（Kd）的单克隆抗体。 抗体可以由通过包括以下步骤的方法制备的杂交瘤产生：（1）用原核细胞来源的人LOX-1细胞外结构域免疫非人动物; （2）从动物收集产生抗体的细胞; （3）将抗体产生细胞与骨髓瘤细胞融合; （4）从上述步骤获得的融合细胞中选择产生与人LOX-1细胞外结构域反应的单克隆抗体的杂交瘤; 和（5）选择产生与来自所选杂交瘤的真核细胞来源的人LOX-1细胞外结构域反应的单克隆抗体的杂交瘤。
-
公开(公告)号：US20080213759A1
公开(公告)日：2008-09-04
申请号：US11722799
申请日：2005-12-20
Applicant: Yasufumi Sato , Hikaru Sonoda , Hideki Ohta
Inventor： Yasufumi Sato , Hikaru Sonoda , Hideki Ohta
CPC classification number: A61K45/06 , A61K31/7088 , A61K38/00 , C07K14/4703 , C07K16/22 , G01N33/574 , G01N2333/515 , G01N2500/04 , Y10T436/143333 , A61K2300/00
Abstract: Because AK022567 has angiogenesis inhibitory activity, it is useful as an angiogenesis inhibitor. Furthermore, 4 splicing variants obtained from the same gene are also useful as an angiogenesis inhibitor. These 5 polypeptides, polynucleotides encoding the polypeptides and antibodies against the polypeptides are useful for screening of a candidate compound as an angiogenesis inhibitor or promoter. A compound obtained from the screening is useful as a medicine and can be used for a preventive or therapeutic agent for an angiogenesis related disease.
Abstract translation: 由于AK022567具有血管发生抑制活性，因此可用作血管生成抑制剂。 此外，从相同基因获得的4个剪接变体也可用作血管发生抑制剂。 这5种多肽，编码多肽的多核苷酸和针对多肽的抗体可用于筛选作为血管生成抑制剂或启动子的候选化合物。 从筛选获得的化合物可用作药物，并且可用于血管生成相关疾病的预防或治疗剂。
-
-
-
-
-
-
-
-
-
Search Results
17
records
(took 0.015 seconds)
